Heidelberg Pharma AG Stock
Price
Target price
€2.99
€2.99
0.340%
-
0.340%
-
26.04.24 / Tradegate
WKN: A11QVV / Name: Heidelberg Pharma / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Heidelberg Pharma
sharewise wants to provide you with the best news and tools for Heidelberg Pharma, so we directly link to the best financial data sources.
Financials
News
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
EQS-News: Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
EQS-News: Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
EQS-News: Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
EQS-News: Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
EQS-News: Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
EQS-News: Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQS-Adhoc: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQS-Adhoc: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQS-News: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board
EQS-News: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board
EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board
EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board
EQS-News: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
EQS-News: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
EQS-News: Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023
EQS-News: Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023